Oligodendrocyte precursor cell control of amyloidosis in alzheimer's disease

Active Grant Awarded

Award ID
FAG101859UR29C7
Recipient
Awarding agency
Obligated
$55,114

Award facts

Assistance listing
93.AG4 National Institute on Aging Training Individual Projects
Completion date 1% complete
Place of performance
Baltimore, MD 21205, USA

Award details come from USAspending.gov.

Description

Abstract
Oligodendrocyte precursor cells (OPCS) are glial restricted progenitors that have the capacity to differentiate into oligodendrocytes to form myelin in the central nervous system (CNS). The persistence of these progenitors beyond the period of developmental myelination and their wide distribution - even in brain regions devoid of oligodendrocytes and myelin - suggests that these cells may perform additional homeostatic roles in the mature CNS. Indeed, OPCS have been shown to functional synapses with neurons, prune neuronal processes, and secrete neuromodulatory signals. Furthermore, OPCS extend dynamic filopodia to survey their local environment and migrate to sites of tissue damage where they contribute to scar/barrier formation. They have also been shown to secrete cytokines and present exogenous antigen to T cells, implicating these glial cells as key effectors of neuroinflammation. Although myelin loss is a well-documented feature of alzheimer's disease (ad), little is known about how OPCS respond to and participate in neurodegeneration. To address these questions, my proposed studies will define the interactions of OPCS with amyloid beta (AΒ), a pathological hallmark of ad. My preliminary studies indicate that OPCS polarize towards AΒ plaques in a mouse model of amyloidosis, and my analysis of published human ad gene expression data reveals upregulation of AΒ binding as well as antigen presentation and TAU binding in a subpopulation of ad-associated OPCS. These findings motivate my central hypothesis that OPCS promote neuroprotection in amyloidosis by limiting AΒ accumulation. To test this hypothesis, I will first define the spatiotemporal evolution of OPC responses to AΒ plaques using whole-hemisphere tissue clearing and in vivo two-photon imaging in a mouse model of amyloidosis. Next, I will examine the role of the OPC-enriched engulfment receptor MEGF11 in AΒ engulfment, given the participation of its drosophila homolog draper and astrocytic homolog MEGF10 in AΒ clearance. Finally, as limited representation of OPCS in bulk tissue samples has hindered efforts to define their disease-associated functions using single cell RNA sequencing (SCRNA-SEQ), I will purify murine OPCS using our OPC reporter mice (MATN4-MEGFP) to perform SCRNA-SEQ, and integrate published human SCRNA-SEQ datasets to (1) test the hypothesis that antigen-presenting "immune OPCS" arise at the expense of differentiating OPCS, and (2) identify protective and pathologic OPC gene expression signatures conserved across neurodegenerative diseases. These studies will be the first to define the complex spatiotemporal dynamics of OPC responses to AΒ aggregation and will identify novel disease-associated OPC populations. By defining novel protective and pathologic functions for OPCS in amyloidosis, these studies have the potential to identify new disease mechanisms and therapeutic targets for ad and many other neurodegenerative disorders while also supporting an integrated training plan that will lay the foundation for my long-term success as a physician-scientist.

Quick answers

Who received award FAG101859UR29C7?

FAG101859UR29C7 was awarded to The Johns Hopkins University by National Institute on Aging (National Institutes of Health) on November 16, 2026.

How much is award FAG101859UR29C7 worth?

$55,114 has been obligated on FAG101859UR29C7.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award